Skip to main content
. 2012 Feb 2;119(17):3917–3924. doi: 10.1182/blood-2011-10-383406

Figure 3.

Figure 3

Phase 2 mobilization data. (A) Change in AML blasts in the peripheral blood expressed as fold-change relative to baseline at 6 hours (n = 37) and 24 hours (n = 31) after administration of plerixafor 0.24 mg/kg. (B) Correlation between CXCR4 expression (CD184 12G5) in the peripheral blood at baseline and AML blast mobilization at 6 hours.